Life Sciences

Allergy Therapeutics plc

Allergy Therapeutics is a Europe-based specialty pharmaceutical company focused upon the diagnosis and treatment of allergy. Allergy Therapeutics has an existing sales base of approximately £70 million per annum, an MHRA-approved manufacturing capability, as well as an established sales and marketing infrastructure in major European markets. In addition, the Company has a number of novel compounds which have already undergone initial clinical evaluation and, once registered, could potentially revolutionise the treatment of allergy.

Market: London Full List

Ticker: AGY

www.allergytherapeutics.com

Lead analyst: Dr Martin Hall